Redburn Atlantic Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces Price Target of $545
Portfolio Pulse from Benzinga Newsdesk
Redburn Atlantic has initiated coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy rating and a price target of $545.
June 27, 2024 | 9:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redburn Atlantic has initiated coverage on Vertex Pharmaceuticals with a Buy rating and a price target of $545.
The initiation of coverage with a Buy rating and a high price target of $545 by Redburn Atlantic is likely to positively impact Vertex Pharmaceuticals' stock price in the short term. Such analyst ratings often lead to increased investor confidence and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100